Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nice quote from a recent online article

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 16, 2021 10:30pm

220 Views

Post# 32314540

RE:Nice quote from a recent online article

Pragmatist wrote:
The article is recent (Oct 20). The quote might be dated, but perhaps is even more valid today.

"H2S prodrugs versus NO prodrugs

Sparatore et al., after working for many years with both NO- and H2S-releasing derivatives of established drugs, have stated that “In the past, we worked for ∼15 years with NO donors, with hundreds of publications and patents, and we can say that H2S and the H2S-releasing drug hybrids are something beyond, and represent a significant technology advancement from, NO-donating hybrids."

No one knows this more than Wallace and Ignarro. They started in NO and it was this work that led them to H2S.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China